1. Scrip
  2. >>COVID-19

Pfizer’s Bourla On Paxlovid Patent Deal And Why A Similar Approach Won't Work For Comirnaty

 
• By Alaric DeArment

Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.

Coronavirus
Pfizer CEO Albert Bourla discussed the latest news about the company's COVID-19 pill at the STAT Summit • Source: Shutterstock

As Pfizer Inc. announced both the submission of the emergency use authorization filing for Paxlovid and signed a licensing agreement with the Medicines Patent Pool (MPP), CEO Albert Bourla offered an explanation for why Pfizer has shared the IP for the oral drug but not for the COVID-19 vaccine Comirnaty.

Bourla spoke at the STAT Summit on 16 November, the same day that Pfizer said it had submitted its EUA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.